In science news around the world, the European Commission proposes that the European Union consider funding military research, more investigations at Japanese universities cast doubts on claims for
a leading hypertension drug, U.S. Fish and Wildlife Service officials plan a culling of barred owls in the Pacific Northwest in hopes of saving the endangered northern spotted owl, and more.
Not exact matches
The company's
lead candidate is Trevyent, a development stage
drug product that utilizes SteadyMed's PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial
hypertension.
United Therapeutics will pay $ 4.46 per share in cash at closing yesterday and an additional $ 2.63 per share in cash upon the achievement of a milestone related to the commercialization of SteadyMed's
leading drug candidate Trevyent for the treatment of Pulmonary Arterial
Hypertension (PAH).
«Although it is unknown how the genes regulate blood pressure,» Zhu added, «our findings contribute to better understanding of blood pressure pathways that can
lead to future development of
drug target for
hypertension and may guide therapy for clinical care.»
«The FDA [U.S. Food and
Drug Administration] has now recommended a gradual reduction in sodium content in many such foods, which should
lead to lower rates of
hypertension as well as cardiovascular disease and deaths,» she said.
Various conditions and medications can
lead to secondary
hypertension, including: Kidney problems; Adrenal gland tumors; Thyroid problems; Certain defects in blood vessels you're born with (congenital); Certain medications, such as birth control pills, cold remedies, decongestants, over-the-counter pain relievers and some prescription
drugs; Illegal
drugs, such as cocaine and amphetamines; Alcohol abuse or chronic alcohol use; Obstructive sleep apnea.